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Abstract
Background: Lymph node (LN) staging in penile cancer has strong prognostic implications. This contrasts with the
high morbidity of extended inguinal LN dissection (LND) or over-treatment of many patients. Therefore, inguinal
dynamic sentinel node biopsy (DSNB) or modified LND is recommended by the European Association of Urology
(EAU) guidelines to evaluate the nodal status of patients with clinically node-negative penile cancer. This study
analyzed the reliability and morbidity of radioguided DSNB in penile cancer under consideration of the current EAU
recommendations in an experienced center with long-term follow-up.
Methods: Thirty-four patients who received primary surgery and had radioguided inguinal DSNB for penile cancer
(≥T1G2) were included (July 2004 to July 2013). Preoperative sentinel LN (SLN) mapping was performed using
lymphoscintigraphy after peritumoral injection of 99mTechnetium nanocolloid on the day of surgery. During
surgery, SLNs were detected using a gamma probe. According to the EAU guidelines, a secondary ipsilateral
radical inguinal LND was performed in patients who had positive SLNs. The false-negative and complication
rates of DSNB were assessed.
Results: A total of 32 patients were analyzed. Two patients were lost to follow-up. A total of 166 SLNs
(median, 5; range, 1–15) were removed and 216 LNs (SLNs + non-SLNs; median, 6; range, 2–19) were dissected. LN
metastases were found in five of the 32 (15.6 %) patients and nine of the 166 (5.4 %) SLNs were found to contain
metastases. None of the remaining 50 non-SLNs contained metastases. In only one of the five SLN-positive
patients, a singular further metastasis was detected by secondary radical inguinal LND. During follow-up
(median, 30.5; range, 5–95 months) no inguinal nodal recurrence was detected. DSNB-related complications
occurred in 11.1 % of explored groins.
Discussion and Conclusions: Radioguided DSNB is a suitable procedure for LN staging in penile cancer
considering the EAU recommendations and with the required experience. Under these circumstances, patients
can be spared from higher morbidity without compromising the detection of LN metastases or therapeutic
implications. Improvement of the methodology used to perform DSNB should be developed further to
decrease the risk of missing LN metastases and to simplify the procedure.
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Background
In penile cancer, lymph node (LN) metastasis is the main
known prognostic factor affecting patients’ survival [1]. A
recent published analysis showed an overall 5-year cancer-
specific survival of patients with primary invasive tumors
of 81 %, but only 56 % of patients with LN metastases sur-
vived the first 5 years after diagnosis [2]. Inguinal LNs are
the first nodal group affected in penile cancer. Early in-
guinal LN dissection (LND) or the resection of clinically
occult LN metastases improves survival compared with
removal when the metastases become clinically apparent
[2–4]. Only one-third of penile cancer patients with re-
gional recurrence are alive after 5 years [4].
Consequently, management of inguinal LN is crucial
for prognosis in patients with penile cancer. Patients
with palpable inguinal nodes are at high risk for LN
metastases. In patients with nonpalpable inguinal nodes
(cN0), the likelihood of the presence of metastasis is
approximately 20–25 % [5]. However, current imaging
techniques are not reliable for detecting micro-metastases
[6]. Moreover, nomograms are also inappropriate for pre-
dicting LN metastases in penile cancer. The accuracy of
currently available predictive models is below 80 % [6].
Therefore, in cases of palpable inguinal LNs, radical
inguinal LND is required. Patients with normal inguinal
nodes and an intermediate or high risk of lymphatic
metastasis (≥T1G2) should also receive invasive LN
staging [6]. Because only 20–25 % of patients with normal
inguinal LNs experience regional lymphatic spread, per-
forming a radical inguinal LND may be an overtreatment
in approximately 80 % of these cases, resulting in consid-
erable morbidity [7]. Complications, such as wound infec-
tion, skin necrosis, wound dehiscence, lymphedema, and
lymphoceles, can occur [8].
To reduce the morbidity associated with radical in-
guinal LND, two invasive procedures are recom-
mended by the European Association of Urology
(EAU) guidelines for patients with nonpalpable nodes:
modified inguinal LND and dynamic sentinel node bi-
opsy (DSNB) [6]. If either modified LND or DSNB
show LN metastases, an ipsilateral radical inguinal
LND should be performed. Fine needle aspiration
cytology (FNAC) has been advised in clinically node-
negative patients by former guidelines [9], but it is no
longer recommended by the EAU owing to low specifi-
city [6]. Moreover, FNAC is not reliable for the detec-
tion of micro-metastases.
Modified inguinal LND includes a limitation of the
dissection field and preservation of the saphenous
vein. As a result, morbidity of the inguinal LND pro-
cedure can be reduced. However, limitation of the
dissection area results in a higher probability of false-
negative cases [8]. According to the current EAU
guidelines, the false-negative rate of modified inguinal
LND is not known [6]. There are few data on this as-
pect of this disease.
DSNB in penile cancer was first described by Cabanas
[10]. The modern sentinel concept in penile cancer
using a radioactive tracer with or without blue dye was
introduced around the turn of the millennium and was
recently further developed [5, 11, 12]. The reliability and
low morbidity of this technique have been reported by
various research groups [7, 13–16].
This study aimed to analyze the reliability of
radioisotope-guided DSNB in penile cancer in an experi-
enced center under consideration of the current EAU
recommendations and with a long-term follow-up.
Methods
Patient population and inclusion criteria for analysis
A total of 49 patients with penile cancer were operated
on at our institute from July 2004 to July 2013 and
documented in a consecutive data bank. In this retro-
spective study, 34 patients with ≥ T1G2 tumors who
received radioisotope-guided inguinal DSNB were in-
cluded. Of these, 32 could be analyzed. Two patients
died a few months after surgery. Causes of death were
not related to complications of the operation or penile
cancer.
All of the patients were informed orally and in writing
regarding inguinal DSNB and penile surgery, and they
gave informed consent.
Surgical treatment
The DSNB was performed in accordance with the
current EAU guidelines [6]. A FNAC, which is still rec-
ommended by others to reduce the false-negative rate,
was not performed [9].
Surgical treatment of the primary tumor depended
on the tumor stage, and included circumcision (n = 5),
resection of the glans with or without circumcision
(n = 11), or partial resection of the penis (n = 16). All in-
cluded patients presented with a tumor stage ≥T1G2 and
received an inguinal DSNB. In 17 patients, the DSNB was
performed in a one-step manner in the same operation.
Fifteen cases received a secondary inguinal DSNB. Two
patients additionally received stage-adapted modified or
radical inguinal LND. In one of these patients, radical
LND of the left groin and a DSNB of the right groin were
performed. The radical LND was indicated because of an
ipsilateral suspicious LN. The other patient had bilateral
enlarged inguinal LNs.
According to the EAU guidelines, a secondary ipsilat-
eral radical inguinal LND was performed in patients
who had positive SLNs (pN1 stage). Secondary inguinal
and pelvic LND was performed if histopathological
evaluation of the inguinal LND specimen revealed two
or more tumor-positive LNs (pN2 stage).
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Sentinel tracer injection
The sentinel tracer (99mTechnetium nanocolloid, radio-
activity ca. 30 MBq) was preoperatively injected peritu-
morally on the day of surgery approximately 4 hours
before the operation (n = 17) (Fig. 1) or in a two-step
procedure in the area of the resection (n = 15). Lym-
phoscintigraphy was then carried out. The SLNs were
intraoperatively detected using two different gamma
probes (C-Trak System, Care Wise, Morgan Hill, CA,
USA; Crystal Probe SG04, Crystal Photonics GmbH,
Berlin, Germany).
Intraoperative procedures and histopathology
LNs identified as SLNs by the gamma probe were dis-
sected. For surgical reasons, LNs other than SLNs dir-
ectly adjoining and adhering to SLNs were also
removed, if in situ separation was not possible.
All LNs were initially cut in 3-mm transverse sections,
routinely processed, and completely embedded in paraf-
fin. Sections that were 4–5 μm thick were stained with
hematoxylin–eosin.
Follow-up
All intra- and postoperative complications were recorded
according to the Clavien–Dindo classification. Follow-up
was performed on an outpatient basis by urologists in the
community in accordance with our instructions. As
recommended by the EAU guidelines [6], for patients
with negative inguinal nodes after local treatment,
follow-up visits included physical examination of the
penis and the groin for detection of local and/or regional
recurrence. On indication, ultrasound, computed tomog-
raphy (CT), or magnetic resonance imaging (MRI) was
used. In patients with positive LNs, CT or MRI scanning
was carried out at 3-monthly intervals during the first
2 years for the detection of regional recurrence or system-
atic disease.
Analysis
We classified DSNB as a false-negative procedure only if
non-SLNs were positive or regional nodal recurrence
developed after a negative SLN procedure. The false-
negative rate of DSNB was calculated according to
the standard definition: false-negative procedures/true-
positive procedures + false-negative procedures.
Ethical approval
The study was approved by the Ethics Committee of the
Carl von Ossietzky University Oldenburg.
Results
A summary of the patient and tumor characteristics is
shown in Table 1.
A total of 166 SLNs (median, 5; range, 1–15) were re-
moved and 216 LNs (SLNs + non-SLNs; median, 6;
range, 2–19) were dissected. LN metastases were found
in five of the 32 (15.6 %) patients and nine of 166
(5.4 %) SLNs were found to contain metastases. None of
the remaining 50 non-SLNs contained metastasis. Of the
five patients with positive SLNs, three presented with
pN1 stage. In secondary radical inguinal LND, a singular
further metastasis was detected only in one of these pa-
tients, while the other two patients had pN2 stage dis-
ease. These two patients were also clinically node
positive. One of these patients, who showed preoperative
enlarged LNs bilaterally, was the only patient with LN
Fig. 1 Peritumoral injection of the sentinel tracer (99mTechnetium nanocolloid)
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metastases in both groins. All other nodal positive patients
presented with unilateral metastases. On secondary iliacal
LND in one of the two cases, pelvic LN metastases were
found (3 of 11 removed LNs were positive). In the other
patient, all further LNs were free of metastases. The histo-
pathological findings are shown in detail in Table 2. Dur-
ing follow-up, no inguinal nodal recurrence was detected.
Accordingly, no patient had false-negative DSNB taking
into account the EAU recommended procedure, including
a secondary radical LN in the case of positive SLNs.
Recurrence of primary tumors was identified in two
patients at 11 or 12 months after surgery by physical
examination or by MRI. In one patient, a Merkel cell
carcinoma of the right thigh was diagnosed simultan-
eously with penile cancer. During follow-up, diffuse me-
tastasis of the Merkel cell carcinoma appeared.
Four patients died during the follow-up. The median
follow-up for these patients was 44.5 months (range,
22–69 months). Reasons for death were pulmonary em-
physema, advanced renal cell carcinoma, and systemic
metastatic disease. In one patient, the cause of death
remained unclear.
DSNB-related complications were assessed in a total
of five patients, but intervention was only required in
three patients (Clavien–Dindo grade III). One patient
underwent a revision operation of both groins owing to
wound infection. Wound healing was achieved by vacuum
bandages and antibiotics after the revision operation
(Clavien–Dindo grade IIIb). Two patients had unilat-
eral inguinal lymphoceles. In these two patients, the
lymphoceles were drained (Clavien–Dindo grade IIIa).
Two other patients suffered from prolonged wound
secretion of the groin and were treated with clinical
surveillance without any re-intervention procedures
(Clavien–Dindo grade I). Five patients had complications
(Clavien–Dindo grade III) after radical LND of the groins.
Two patients underwent a revision operation of one groin
owing to wound infection (Clavien–Dindo grade IIIb).
Wound healing was achieved either by vacuum bandages
and antibiotics after the revision operation or secondary
operation. Drainage of lymphoceles was performed in the
other three patients (Clavien–Dindo grade IIIa). There-
fore, the complication rate concerning DSNB alone was
11.1 % (per groin). Complications occurred in all patients
with radical inguinal LND (100 %, per groin). In these pa-
tients, an intervention was always required.
Discussion
In this study, we performed a retrospective analysis of pa-
tients who underwent radioisotope-guided DSNB in a
center with wide expertise in sentinel procedures related
to urological malignancies. The reliability of this approach
was investigated under consideration of the current
EAU guidelines (2014) [6]. The median follow-up was
30.5 months in the present study. Because recurrence
of tumors occurs typically within 2 years, a false-negative
rate of DSNB should become clinically apparent at that
time [17]. Accordingly, a median follow-up of 30.5 months
is sufficient to address this issue. This is underlined by the
fact that, in our study, no inguinal recurrence was de-
tected if patients who were only followed up for at least
24 months (n = 19; median follow-up, 60 months; range,
24–95 months) were analyzed.
A DSNB or an EAU recommended procedure [6], in-
cluding secondary LND in patients with positive SLNs,
showed reliable results in the examined population. In
only one patient with a tumor-positive SLN, a singular
further LN metastasis was detected on secondary radical
LND. None of the patients suffered recurrence of in-
guinal LN. Our results are in line with recent studies in
Table 1 Summary of patient and tumor characteristics
Characteristic No. of patients
Total 32
Grade by T stage
T1 20


















Table 2 Nodal status related to histopathological tumor stage
Stage pN0 pN+ inguinal pN+ pelvic
(n = 26) (n = 5) (n = 1)
pT1 G2 16 (89 %) 2 0
pT1 G3 1 (50 %) 1 1
pT2 G1 1 (100 %) 0 0
pT2 G2 8 (89 %) 1 0
pT3 G3 1 (50 %) 1 0
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which DSNBs showed high reliability. In a prospective
study, Lam et al. analyzed a total of 264 patients with
penile cancer undergoing DSNB [14]. The false-negative
rate per patient was 6 %. Fuchs et al. found an inguinal
nodal recurrence in only 3.7 % of their patients [18],
while Leijte et al. investigated 323 patients and calcu-
lated a false-negative rate of 7 % per groin [19]. In a re-
cent national multicenter study from Denmark, the
overall false-negative rate was 13.3 % per patient [20].
However, caution is advised, because in our study, 56 %
of the patients had a low stage (T1G2). At a median of
30 months, there are still many patients at risk for recur-
rence. For this reason, our results may not reflect the
outcome of series with a different mixture of patients. In
an initial DSNB series by Kirrander et al., the recurrence
rate was 15 % [21]. However, in their study, 50 % of the
patients had T2 or greater primary tumors.
Some more potential limitations of this study need to
be discussed. The results from the present study are
based on the data of one center and on a relatively small
cohort. In this context, the low incidence of penile can-
cer in Germany has to be taken into account. However,
this study represents the largest published German
DSNB series in penile cancer to date.
Another limitation is the fact that the DSNB was per-
formed either primarily or secondarily after resection of
penile tumors in the present study. LN metastases were
found in five patients. Three patients underwent primary
DSNB, and two underwent a secondary procedure after
resection of the primary tumor. However, a study by
Graafland et al. suggested that the results of a primary
DSNB were equal to those of a two-step procedure [22].
In their study, 40 patients who had undergone DSNB
after previous resection of the primary penile tumor
were analyzed, and no recurrences developed in the
groins during a median follow-up of 28 months.
Whether a DSNB should be performed is still contro-
versial, mostly because a false-negative result is associ-
ated with a significant risk of death. Therefore, some
authors have stressed that a DSNB cannot be considered
as a real gold standard for evaluation of patients with
cN0 penile carcinoma [23, 24]. This is because initial re-
sults of DSNB in penile cancer show a high false-
negative rate of 19.2–22 % [7, 25]. In a recent study, an
experienced research group in Amsterdam showed that
the 5-year cancer-specific survival for all patients with
pN+ disease is better than that in series that prefer pri-
mary inguinal LND in all patients who are considered at
risk for LN metastases [2]. After performing several modi-
fications to the DSNB procedure, the false-negative rate
dropped to 4.8 % [7]. As mentioned above, other studies
have shown that DSNB is a reliable and safe method for
inguinal LN staging in penile cancer [7, 13–16]. Moreover,
excellent results concerning sensitivity, false-negative
rates, and complication rates for DSNB have been re-
ported in several studies [14, 19, 26]. These findings show
the importance of methodology in DSNB. However,
the conclusion cannot be made that a lower false-negative
rate is only caused by these modifications; experience in
performing DSNB might also be a contributing factor.
Re-routing of the radioactive tracer due to tumor
blockage of lymph vessels has been proposed as a mech-
anism for increasing the risk for false-negative SLN pro-
cedures [27]. One fundamental problem with the
sentinel technique is that when LNs are fully metasta-
sized or lymph pathways are blocked, the afferent lymph
will be directed to other LNs/non-SLNs [28]. Therefore,
Leijte et al. added preoperative ultrasound of the groins
with FNAC of suspicious nodes to identify and cytologic-
ally examine possible blocked SLNs [7]. This procedure
was advised in clinically node-negative patients in former
guidelines [9], but it is no longer recommended by the
EAU owing to the low specificity of FNAC [6]. The
current EAU guidelines take the possibility of fully metas-
tasized LNs or blocked lymphatic vessels into account by
recommending a primary radical inguinal LND in patients
with clinical enlarged LNs or a secondary radical LND in
cases with tumor-positive SLNs, respectively.
Further investigations have been made to improve the
reliability of DSNBs. Brouwer et al. recently showed in-
docyanine green-99mTechnetium-nanocolloid as a hybrid
radioactive and fluorescent tracer for performing DSNB
[12]. This tracer was successfully used for combined
radio- and fluorescence-guided DSNB in penile carcinoma.
A large improvement in optical SLN detection compared
with blue dye has been achieved using this new approach.
The low risk of a false-negative rate in DSNB has to
be weighed against the morbidity of conventional in-
guinal LND in penile cancer. Inguinal LND is a potential
over-treatment in patients without regional LN involve-
ment, which constitutes about 80 % of those with cN0
disease [29]. The rate of complications of DSNB in the
present study was 11.1 % (per groin), which is in line
with recent studies [21, 30]. We found no cancer in
non-SLNs. This suggests that more extensive node sam-
pling is unnecessary and may contribute to morbidity.
Other authors have reported a lower rate of complica-
tions after DSNB [7, 14, 18, 24]. Leijte et al. were able to
decrease the complication rate of inguinal DSNB from
10.2 to 5.7 % [7]. In a systemic review, Neto et al.
reported a complication rate of 3.6 % when performing
inguinal DSNB [31]. However, inguinal LND is a procedure
with a considerably higher complication rate of 40–50 %
[23, 31]. Protzel et al. pointed out that the potential advan-
tage of reduced morbidity with DSNB appears to be less
pronounced compared with modified inguinal LND [8].
However, there are only limited data regarding the false-
negative rate of modified LND [6]. Therefore, further
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studies are needed to compare the false-negative rates of
DSNB and modified LND.
Conclusions
Radioguided DSNB is a suitable procedure for LN sta-
ging in penile cancer patients under consideration of the
EAU recommended procedure in experienced centers.
Under these circumstances, patients can be spared from
higher morbidity without compromising the detection of
LN metastases or therapeutic implications in LN positive
patients. Improvement of the methodology used to per-
form DSNB (e.g., new tracers) should be developed fur-
ther to decrease the risk of missing LN metastases and
to simplify the procedure.
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